Angiogenesis inhibitors have produced significant advances in the treatment of several
tumors including colorectal, lung, ovarian and renal carcinomas. These agents, however …

VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma,
gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a …

Introduction: Angiogenesis is an important component of certain normal physiological
processes, but aberrant angiogenesis contributes to some pathological disorders and in …

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is thought to play a
critical role in tumor growth and metastasis. Consequently, anti-VEGF therapies are being …

Angiogenesis, a well-recognized characteristic of malignancy, has been exploited more than
any other pathway targeted by biologic anti-neoplastic therapies. Vascular endothelial …

Computational and experimental studies were applied to the discovery of a series of novel
vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors. Eight compounds …

Interaction of numerous signaling pathways in endothelial and mesangial cells results in
exquisite control of the process of physiological angiogenesis, with a central role played by …

Angiogenesis is a critical hallmark of malignancy, and attempts to inhibit this process have
characterized the age of biologic anticancer therapies for solid tumors. VEGF receptor-2 is …

New blood vessels formation from the existing vasculature is called angiogenesis. It is an
essential physiological process for the growth of cells, tissue repair, wound healing, and …

Abstract Learning Objectives After completing this course, the reader will be able to:
Compare and contrast the mechanism of action for angiogenesis inhibitors currently being …